Home » Stocks » SQZ

SQZ Biotechnologies Company (SQZ)

Stock Price: $11.79 USD 0.13 (1.11%)
Updated May 7, 2021 4:00 PM EDT - Market closed
Market Cap 317.85M
Revenue (ttm) 21.00M
Net Income (ttm) -50.52M
Shares Out 27.88M
EPS (ttm) -9.35
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 7
Last Price $11.79
Previous Close $11.66
Change ($) 0.13
Change (%) 1.11%
Day's Open 11.65
Day's Range 11.29 - 12.05
Day's Volume 593,883
52-Week Range 11.28 - 36.49

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, announced today that it will present new data on th...

1 week ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today shared preclinical data from its next generat...

3 weeks ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that management will be participatin...

1 month ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today reported full year 2020 financial results and...

1 month ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that its team will present ...

1 month ago - Business Wire

SQZ Biotechnologies Company (SQZ) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

1 month ago - Zacks Investment Research

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that Armon Sharei, PhD, chief execut...

2 months ago - Business Wire

The cell-squeezing specialist priced a new stock issue.

2 months ago - The Motley Fool

SQZ Biotechnologies Co (NYSE: SQZ) prices its underwritten public offering of 3 million common shares at $20 per share. Underwriters have an option to purchase up to an additional 450,000 shares.

2 months ago - Benzinga

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ) (“SQZ”), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that it has commenc...

2 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that the company's Investigational ...

3 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE: SQZ), a cell therapy company developing novel potential treatments for multiple therapeutic areas, announced today that the Immune Tolerance...

3 months ago - Business Wire

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies (NYSE:SQZ), a cell therapy company developing novel treatments for multiple therapeutic areas, today announced that Armon Sharei, PhD, chief execut...

5 months ago - Business Wire

The IPO market is taking a break during the shortened Thanksgiving week, with just one IPO and two SPACs scheduled to raise $900 million. Russian e-commerce company Ozon Holdings plans to raise $750 mil...

Other stocks mentioned: ALGM, AVIR, BDSX, GATO, GLTO, LESL, LU ...
5 months ago - Seeking Alpha

WATERTOWN, Mass.--(BUSINESS WIRE)--SQZ Biotechnologies Company (NYSE: SQZ) (“SQZ”) today announced the pricing of its initial public offering of 4,411,765 shares of common stock at a public offering pri...

6 months ago - Business Wire

About SQZ

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops transformative cell therapies for patients with cancer, infectious diseases, and other serious conditions. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with other immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develop... [Read more...]

Industry
Biotechnology
IPO Date
Oct 30, 2020
Stock Exchange
NYSE
Ticker Symbol
SQZ
Full Company Profile

Financial Performance

In 2020, SQZ's revenue was $21.00 million, an increase of 4.42% compared to the previous year's $20.11 million. Losses were -$50.52 million, 56.9% more than in 2019.

Financial Statements

Analyst Forecasts

According to 4 analysts, the average rating for SQZ stock is "Strong Buy." The 12-month stock price forecast is 37.50, which is an increase of 218.07% from the latest price.

Price Target
$37.50
(218.07% upside)
Analyst Consensus: Strong Buy